Your session is about to expire
← Back to Search
Thermal Ablation
NanoTherm Ablation for Prostate Cancer
N/A
Waitlist Available
Research Sponsored by MagForce USA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months (+/- 1 month)
Awards & highlights
Summary
This trial evaluates NanoTherm ablation, a treatment that uses tiny particles to heat and destroy small cancerous areas in the prostate. It targets patients with intermediate-risk prostate cancer who have small lesions in Gleason 3+4 disease. The treatment aims to offer a less invasive option compared to traditional methods like surgery or radiation, by using heat to kill cancer cells in a very targeted area. NanoTherm ablation uses magnetic nanoparticles to heat and destroy cancer cells, a method that has shown feasibility and good tolerability in recent clinical trials.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 months (+/- 1 month)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months (+/- 1 month)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Rate of Ablation Success
Secondary study objectives
Adverse Event Rate
Trial Design
1Treatment groups
Experimental Treatment
Group I: Ablation ArmExperimental Treatment1 Intervention
Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.
Find a Location
Who is running the clinical trial?
MagForce USALead Sponsor
1 Previous Clinical Trials
100 Total Patients Enrolled
David Hammond, MSStudy DirectorMagForce USA
Share this study with friends
Copy Link
Messenger